Demographic and clinical characteristics
| Characteristic . | Overall, N = 136∗ . | Site for venetoclax escalations . | ||
|---|---|---|---|---|
| All IP, n = 27∗ . | Any IP, n = 35∗ . | OP, n = 74∗ . | ||
| Age at venetoclax start, y | 70.27 (61.17, 76.90) | 71.68 (60.97, 79.25) | 66.47 (54.99, 72.64) | 70.49 (62.83, 77.11) |
| Race | ||||
| White | 117 (86%) | 21 (78%) | 28 (80%) | 68 (92%) |
| Black or African American | 11 (8.1%) | 3 (11%) | 6 (17%) | 2 (2.7%) |
| Asian | 3 (2.2%) | 0 (0%) | 1 (2.9%) | 2 (2.7%) |
| Other/unknown | 5 (3.7%) | 3 (11%) | 0 (0%) | 2 (2.7%) |
| ECOG performance status | ||||
| 0 | 57 (42%) | 10 (37%) | 10 (29%) | 37 (50%) |
| 1 | 11 (8.1%) | 1 (3.7%) | 2 (5.7%) | 8 (11%) |
| 2 | 2 (1.5%) | 0 (0%) | 1 (2.9%) | 1 (1.4%) |
| Unknown | 66 (49%) | 16 (59%) | 22 (63%) | 28 (38%) |
| Creatinine clearance across all escalations | ||||
| Never <60 mL/min per 1.73 m2 | 102 (75%) | 17 (63%) | 26 (74%) | 59 (80%) |
| <60 mL/min per 1.73 m2 at least once | 34 (25%) | 10 (37%) | 9 (26%) | 15 (20%) |
| Size of largest LN (in cm) at venetoclax initiation | 2.10 (1.50, 4.00) | 3.25 (2.00, 5.48) | 3.00 (2.00, 4.00) | 2.00 (1.00, 3.70) |
| Unknown | 3 | 1 | 2 | 0 |
| ALC (in mcL⁻1) at venetoclax initiation | 2.00 (0.90, 16.65) | 33.20 (3.40, 100.25) | 8.50 (1.70, 25.75) | 1.00 (0.80, 2.20) |
| Unknown | 1 | 0 | 0 | 1 |
| TLS risk | ||||
| Low | 91 (69%) | 7 (27%) | 21 (64%) | 63 (86%) |
| Medium | 30 (23%) | 12 (46%) | 9 (27%) | 9 (12%) |
| High | 11 (8.3%) | 7 (27%) | 3 (9.1%) | 1 (1.4%) |
| Unknown | 4 | 1 | 2 | 1 |
| Venetoclax as frontline TX | 48 (35%) | 7 (26%) | 7 (20%) | 34 (46%) |
| Paired medication | ||||
| Rituximab† | 16 (12%) | 5 (19%) | 4 (11%) | 7 (9.5%) |
| Obinutuzumab | 66 (49%) | 3 (11%) | 13 (37%) | 50 (68%) |
| Ibrutinib | 4 (2.9%) | 1 (3.7%) | 3 (8.6%) | 0 (0%) |
| None | 50 (37%) | 18 (67%) | 15 (43%) | 17 (23%) |
| Paired medication before venetoclax | 76 (56%) | 7 (26%) | 17 (49%) | 52 (70%) |
| Laboratory TLS rate | 8 (5.9%) | 4 (15%) | 2 (5.7%) | 2 (2.7%) |
| Isolated hyperuricemia | 15 (11%) | 4 (15%) | 5 (14%) | 6 (8.1%) |
| Characteristic . | Overall, N = 136∗ . | Site for venetoclax escalations . | ||
|---|---|---|---|---|
| All IP, n = 27∗ . | Any IP, n = 35∗ . | OP, n = 74∗ . | ||
| Age at venetoclax start, y | 70.27 (61.17, 76.90) | 71.68 (60.97, 79.25) | 66.47 (54.99, 72.64) | 70.49 (62.83, 77.11) |
| Race | ||||
| White | 117 (86%) | 21 (78%) | 28 (80%) | 68 (92%) |
| Black or African American | 11 (8.1%) | 3 (11%) | 6 (17%) | 2 (2.7%) |
| Asian | 3 (2.2%) | 0 (0%) | 1 (2.9%) | 2 (2.7%) |
| Other/unknown | 5 (3.7%) | 3 (11%) | 0 (0%) | 2 (2.7%) |
| ECOG performance status | ||||
| 0 | 57 (42%) | 10 (37%) | 10 (29%) | 37 (50%) |
| 1 | 11 (8.1%) | 1 (3.7%) | 2 (5.7%) | 8 (11%) |
| 2 | 2 (1.5%) | 0 (0%) | 1 (2.9%) | 1 (1.4%) |
| Unknown | 66 (49%) | 16 (59%) | 22 (63%) | 28 (38%) |
| Creatinine clearance across all escalations | ||||
| Never <60 mL/min per 1.73 m2 | 102 (75%) | 17 (63%) | 26 (74%) | 59 (80%) |
| <60 mL/min per 1.73 m2 at least once | 34 (25%) | 10 (37%) | 9 (26%) | 15 (20%) |
| Size of largest LN (in cm) at venetoclax initiation | 2.10 (1.50, 4.00) | 3.25 (2.00, 5.48) | 3.00 (2.00, 4.00) | 2.00 (1.00, 3.70) |
| Unknown | 3 | 1 | 2 | 0 |
| ALC (in mcL⁻1) at venetoclax initiation | 2.00 (0.90, 16.65) | 33.20 (3.40, 100.25) | 8.50 (1.70, 25.75) | 1.00 (0.80, 2.20) |
| Unknown | 1 | 0 | 0 | 1 |
| TLS risk | ||||
| Low | 91 (69%) | 7 (27%) | 21 (64%) | 63 (86%) |
| Medium | 30 (23%) | 12 (46%) | 9 (27%) | 9 (12%) |
| High | 11 (8.3%) | 7 (27%) | 3 (9.1%) | 1 (1.4%) |
| Unknown | 4 | 1 | 2 | 1 |
| Venetoclax as frontline TX | 48 (35%) | 7 (26%) | 7 (20%) | 34 (46%) |
| Paired medication | ||||
| Rituximab† | 16 (12%) | 5 (19%) | 4 (11%) | 7 (9.5%) |
| Obinutuzumab | 66 (49%) | 3 (11%) | 13 (37%) | 50 (68%) |
| Ibrutinib | 4 (2.9%) | 1 (3.7%) | 3 (8.6%) | 0 (0%) |
| None | 50 (37%) | 18 (67%) | 15 (43%) | 17 (23%) |
| Paired medication before venetoclax | 76 (56%) | 7 (26%) | 17 (49%) | 52 (70%) |
| Laboratory TLS rate | 8 (5.9%) | 4 (15%) | 2 (5.7%) | 2 (2.7%) |
| Isolated hyperuricemia | 15 (11%) | 4 (15%) | 5 (14%) | 6 (8.1%) |